0
0
Cambridge, Mass. — Sarepta Therapeutics, a leading developer of gene therapies for muscular dystrophy, has declined a request from the U.S. Food and Drug Administration (FDA) to suspend distribution of its flagship therapy following three reported patient deaths, including a new fatality involving an experimental treatment for another form of muscular dystrophy.
FDA Action and Sarepta’s Response
The FDA recently placed a hold on Sarepta’s clinical trials for limb-girdle muscular dystrophy gene therapies, citing safety concerns after three trial participants died due to acute liver failure. Alongside the clinical hold, the FDA revoked Sarepta’s platform technology designation and called for the company to voluntarily pause shipments of Elevidys, its approved gene therapy for Duchenne muscular dystrophy (DMD). Sarepta, however, refused, stating that it sees “no new or altered safety signals” for the approved use in younger, ambulatory Duchenne patients and intends to keep the therapy available to those individuals.
“We anticipate ongoing discussions and information sharing with the FDA,” the company said, emphasizing its commitment to patient access for unmet medical needs.
Details of Patient Deaths
Sarepta first paused shipments of Elevidys for older, non-ambulatory boys last month after two deaths among teenage patients treated for DMD. Those fatalities were linked to acute liver failure, a known but rare side effect of the therapy, especially at higher doses required for older or heavier patients.
This week, Sarepta confirmed a third death: a 51-year-old man who was part of a clinical trial for a different gene therapy, SRP-9004, targeting limb-girdle muscular dystrophy. The company notified the FDA of the incident last month. Sarepta noted that this therapy involves a different manufacturing process and dosage than Elevidys, and that the trial is being discontinued.
Regulatory and Market Impact
-
The deaths have prompted the FDA to investigate and consider further regulatory actions, including updates to prescribing information and discussions around additional immunosuppression strategies to mitigate liver risks.
-
Sarepta’s stock dropped more than 35% following the news of the third fatality, reflecting shaken investor confidence.
-
Elevidys, which received full FDA approval in 2023 for DMD patients aged four and older—including those unable to walk—is currently the only approved gene therapy for the rare muscle-wasting condition.
Company and FDA Statements
Both Sarepta and the FDA reaffirm their focus on patient safety. The FDA has emphasized its willingness to act quickly when new safety risks emerge, noting that it “will not allow products whose harms are greater than benefits”. Sarepta insists that for younger Duchenne patients, the benefits outweigh the risks and highlights the role of new expert panels to guide future safety protocols.
The Ongoing Debate
Elevidys costs more than $3 million for a one-time infusion and has been administered to over 800 patients so far. While initial FDA approval was granted conditionally—in part due to questions about long-term efficacy—the recent deaths have intensified scrutiny of both safety and regulatory rigor around gene therapy for rare diseases.
Disclaimer
This article summarizes current developments as of July 20, 2025, regarding Sarepta Therapeutics, the FDA, and gene therapy for muscular dystrophy, based on publicly available news sources. Medical details are evolving and subject to further regulatory action or findings. For medical guidance, diagnosis, or treatment options, readers should consult healthcare professionals. The information provided should not be construed as investment advice or a substitute for professional consultation.
